Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05562778 · ClinicalTrials.gov registry record · NA
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
A NA study of Gynecologic Cancer and Hereditary Cancer Syndrome, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 4
- Study locations
NCT05562778: Recruiting NA study of Gynecologic Cancer and Hereditary Cancer Syndrome, sponsored by Weill Medical College of Cornell University.
NCT05562778 is a NA study of Gynecologic Cancer and Hereditary Cancer Syndrome that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 150 participants, below the 762-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05562778, a NA study of Gynecologic Cancer and Hereditary Cancer Syndrome, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 4
- Study locations
Study Summary
In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic. Furthermore, the investigators aim to evaluate facilitators of inequity in regard to patient access to and utilization of genetic testing services.
Primary Outcome
The proportion of high-risk patients that are recommended genetic testing for familial cancer syndromes in the chatbot vs. usual care arms.
Conditions Studied
Interventions
- OTHER Chatbot
Study Locations (4)
New York
- NYP Brooklyn Methodist Hospital - Brooklyn
- NYP Lower Manhattan Hospital - New York
- Weill Cornell Medicine - New York
- NYP Medical Group Queens - Queens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-01-15 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT05562778 shows while recruiting
NCT05562778 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 762-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Gynecologic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Chatbot is the first listed.
NCT05562778 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05562778 about?
NCT05562778 is a clinical study titled "Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment". In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if th...
What is the current status of trial NCT05562778?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2023-01-15. Estimated completion is 2026-12.
What conditions does trial NCT05562778 study?
This clinical trial studies the following conditions: Gynecologic Cancer, Hereditary Cancer Syndrome.
What interventions are being tested in trial NCT05562778?
The interventions under investigation include: Chatbot (OTHER).
Who is sponsoring clinical trial NCT05562778?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05562778 being conducted?
This trial has 4 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05562778's enrollment target sits among peer trials
150 14th of 55 higher than 41 of 55 other Gynecologic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gynecologic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Activity Coaching During Pelvic Radiation Therapy
RECRUITING · NA
-
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
RECRUITING · NA
-
Improve Cancer-related Cognitive Impairment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI